Nurix Says Sanofi Halts Phase 1 Trial of STAT6 Degrader SAR448272

Sanofi will discontinue the Phase 1 trial and terminate the SAR448272 program. Nurix does not anticipate future development, regulatory or commercial milestone payments or royalties for SAR448272; its cash runway guidance is unchanged, with $1.1B as of August 31, 2026, sufficient into the second ha…